Meeting
2024 ASCO Annual Meeting
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).
Authors
Dan Liu
Beijing Cancer Hospital, Beijing, China
Dan Liu , Lin Shen , Sumitra Ananda , Dan Cao , Catherine HyeWon Han , Jermaine Coward , Yee Chao , Wei Li , Prashanth Hari Dass , Chih-Hung Hsu , Adnan Nagrial , Yuan Huang , Vinod Ganju , Xiaobing Chen , Deirdre J. Cohen , Rajiv Kumar , Li-Yuan Bai , Ying Yuan , Tai-Jan Chiu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05031494
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4146)
DOI
10.1200/JCO.2024.42.16_suppl.4146
Abstract #
4146
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The efficacy and safety of anti–PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.
First Author: Jiaying Chen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Gang Jin
Poster
2021 ASCO Annual Meeting
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.
First Author: Lingdi Zhao